Trial ID or NCT#

NCT02253992

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.

Official Title

A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Susan M. Swetter, MD
Susan M. Swetter, MD
Dermatologist, Dermatologic oncologist, Cutaneous oncology specialist, Melanoma specialist
Professor of Dermatology
Bernice Kwong, MD
Bernice Kwong, MD
Dermatologist, Dermatologic oncologist, Cutaneous oncology specialist, Dermato-oncology specialist, Dermatopathologist
Clinical Professor, Dermatology

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061